Skip to main content

Silverback Therapeutics, Inc. (SBTX)

NASDAQ: SBTX · IEX Real-Time Price · USD
9.12 0.09 (1.00%)
Oct 26, 2021 2:29 PM EDT - Market open
Market Cap323.39M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out34.88M
EPS (ttm)-3.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume498,232
Open9.15
Previous Close9.03
Day's Range8.79 - 9.55
52-Week Range8.79 - 63.41
Betan/a
AnalystsBuy
Price Target45.40 (+397.8%)
Earnings Daten/a

About SBTX

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 l...

IndustryBiotechnology
IPO DateDec 4, 2020
Employees76
Stock ExchangeNASDAQ
Ticker SymbolSBTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SBTX stock is "Buy." The 12-month stock price forecast is 45.40, which is an increase of 397.81% from the latest price.

Price Target
$45.40
(397.81% upside)
Analyst Consensus: Buy

News

Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

3 weeks ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

New York, New York--(Newsfile Corp. - October 1, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Su...

3 weeks ago - Newsfile Corp

Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial

Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). D...

1 month ago - Benzinga

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Co...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

1 month ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX).

1 month ago - PRNewsWire

Why Are Silverback Therapeutics Shares Falling On Monday?

Silverback Therapeutics Inc (NASDAQ: SBTX) stock dropped to the lowest level since its IPO in December 2020 in reaction to interim data from SBT6050 Phase 1/1b trial for solid tumors. The trial in advan...

1 month ago - Benzinga

Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Med...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

1 month ago - Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

1 month ago - Business Wire

Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

2 months ago - Business Wire

Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

2 months ago - Business Wire

Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Li...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

3 months ago - Business Wire

Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

4 months ago - Business Wire

Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

4 months ago - Business Wire

Silverback Therapeutics Reports First Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

5 months ago - Business Wire

Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

6 months ago - Business Wire

Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

6 months ago - Business Wire

Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

7 months ago - Business Wire

Silverback Therapeutics to Present at Upcoming Investor Conferences

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

8 months ago - Business Wire

SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline

Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: SVB Leerink...

9 months ago - Benzinga

Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other symbols:CARARDXCNNEMPLNSEER
10 months ago - Benzinga

Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Pur...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

10 months ago - Business Wire

U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...

Other symbols:KNTEPOWWSEERYQ
10 months ago - Seeking Alpha

Biotech IPOs Stay Hot With Seer, Silverback Set To Trade

The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.

Other symbols:SEER
10 months ago - Investors Business Daily

Silverback Therapeutics prices IPO at $21/share, will raise $241M in 4th Wash. state IPO of 2020

Silverback Therapeutics will raise $241.

10 months ago - GeekWire

Silverback Therapeutics Announces Pricing of Initial Public Offering

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

10 months ago - Business Wire